- Lexaria, a global innovator in drug delivery platforms, has, through its patented DehydraTECH(TM) technology, proven to enhance the performance of several categories of fat-soluble active molecules and drugs
- Since 2018, human clinical studies on the technology have yielded positive results, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world
- With the strides made so far, Lexaria looks to grow its revenue and commercial opportunities through licensing
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains committed to its mission to provide healthier delivery methods of drugs and other Active Pharmaceutical Ingredients (“APIs”). This is made possible through its patented drug delivery technology, DehydraTECH(TM), proven to enhance the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats.
The company’s efforts have focused on several key segments, including hypertension, diabetes, antivirals, epilepsy, nicotine replacement, and more. This has been an ongoing process since 2016, with positive results achieved from various clinical studies thus far, showing up to 17x brain absorption improvements for oral administration of APIs. In 2021, for instance, the nicotine oral mucosal animal absorption study, NIC-A21-1, demonstrated a 10x to 20x reduction in time to deliver peak levels of nicotine, as well as a 1.7x to 6.6x improvement in nicotine levels in the bloodstream (https://ibn.fm/HrpZL).
This is enabled by DehydraTECH’s specific design for formulating and delivering lipophilic drugs and APIs. By increasing their effectiveness and improving the way they enter the bloodstream, DehydraTECH can offer a wide range of benefits, such as a significant increase in bioavailability, increased brain absorption, improving the speed of onset, masking unwanted tastes, and reduced drug administration costs.
Human clinical studies have been conducted since 2018, with more on the way, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world. From 2018 to 2022, four human clinical studies on the potential treatment of hypertension were completed, evidencing lower blood pressure (“BP”) with zero serious adverse events. Lexaria is now closer than ever to submitting its Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial with the U.S. Food and Drug Administration.
For the first half of the 2023 calendar year, animal studies on using DehydraTECH-processed CBD for potentially treating diabetes demonstrated positive results such as reduced triglyceride levels, weight loss, and improved cholesterol levels. . .
“This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths,” noted Chris Bunka, Lexaria’s CEO (https://ibn.fm/D0s8F).
With the strides made, Lexaria looks to grow its revenue and commercial opportunities through licensing. Given its versatile application areas, the technology can be licensed by both the consumer-packaged goods industry and the drug and pharmaceutical sector. Its suitability cuts across a growing range of consumer product formats, such as registered drugs, nutraceuticals, oral suspensions, topical applications, capsules, pills, tablets and more.
The progress achieved thus far by Lexaria is remarkable. Its goals are also much more significant, as evidenced by the time and resources invested into DehydraTECH development. The efforts so far affirm the company’s commitment to providing healthier delivery methods for drugs and other APIs. They also assert its commitment to creating shareholder value and stamping its position as a leader in its segment.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com
MissionIR is powered by IBN
